MELISSA LOWMAN: Open Payments
NPI 1235837279 · RUSSELLVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$391 in 20 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $391
Food & beverage: $391
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 3 | $82 |
| Novartis Pharmaceuticals Corporation | 4 | $81 |
| Amgen Inc. | 4 | $81 |
| SCPHARMACEUTICALS INC. | 3 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| AKEBIA THERAPEUTICS INC | 1 | $15 |
Products named: KRYSTEXXA, FUROSCIX, Kerendia, Veltassa, FARXIGA, JARDIANCE, Vafseo.
Industry payments across AR — which companies pay providers there.
